Reports
Sale
Amyotrophic Lateral Sclerosis Market Size, Share, Forecast: By Type: Sporadic ALS, Familial ALS; By Treatment Type: Chemotherapy, Stem Cell Therapy, Physical Therapy, Others; By Diagnosis Method: Electromyogram, MRI, Blood and Urine Tests, Others; By End User; By Distribution Channels; Regional Analysis; Competitive Landscape; 2024-2032
Amyotrophic Lateral Sclerosis Market Outlook
The amyotrophic lateral sclerosis market size was valued at USD 716.3 million in 2023, driven by the increasing incidence of amyotrophic lateral sclerosis across the globe. The market is expected to grow at a CAGR of 5.5% during the forecast period of 2024-2032, with the values likely to rise from USD 755.6 million in 2024 to USD 1159.1 million by 2032.
Amyotrophic Lateral Sclerosis: Introduction
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease that causes loss of muscle control. It begins with muscle weakness and twitching in the arms or legs, muscle cramps, spasms, difficulty swallowing, slurred speech. In rare cases, patients may also experience trouble with decision making or develop a form of dementia. ALS causes motor neurons to deteriorate and die. Motor neurons extend from the brain to spinal cord and are responsible for voluntary muscle movements such as walking and talking.
There is no single test for ALS diagnosis. It is identified through a series of neurological exams that analyze reflexes, muscle strength and other responses.
Amyotrophic Lateral Sclerosis Market Analysis
ALS is a fatal disease projected to affect approximately 376,674 people by 2040. The current ALS treatments include oral medications like Radicava ORS® (edaravone) and combination therapies like AMX0035, which comprises two medications sodium phenylbutyrate and tauroursodeoxycholic acid, have been commonly used as a treatment method. However, with increasing medical advances and high amyotrophic lateral sclerosis market demand, novel treatment methods have surfaced the market.
Relyvrio (sodium phenylbutyrate/taurursodiol) is one of the most recent oral medications approved by the US Food and Drug Administration (FDA). Northwestern University scientists have been working on a new experimental drug called NU-9. As per scientists, this drug has an advanced effect when given in combination to riluzole and edaravone (other ALS treatment drugs). Stem cell therapies and gene therapies are also a key area of interest among researchers, set to aid the amyotrophic lateral sclerosis market growth in the upcoming years.
In April 2023, FDA granted an accelerated approval for QALSODY™ (tofersen), the first treatment to target the genetic cause of ALS. It was developed in a Biogen and Ionis Pharmaceutical collaboration to specifically target the RNA produced by SOD1 gene, present in affected patients. Other ALS related genes including C9orf72, TBK1, and NEK1, are also under investigation for creating potential and effective drugs for patients.
Amyotrophic Lateral Sclerosis Market Segmentation
Market Breakup by Type
- Sporadic ALS
- Familial ALS
Market Breakup by Treatment Type
- Chemotherapy
- Stem Cell Therapy
- Physical Therapy
- Others
Market Breakup by Diagnosis Method
- Electromyogram
- MRI
- Blood and Urine Tests
- Spinal Tap
- Muscle Biopsy
- Others
Market Breakup by End User
- Hospitals and Clinics
- Cancer Research Centres
- Others
Market Breakup by Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Amyotrophic Lateral Sclerosis Market Overview
North America has led the global market owing to the presence of a well-equipped research and healthcare infrastructure. The United States being an innovative hub with several healthcare giants also fuels the market size. Understanding the seriousness of the disease, unique initiatives like the Ice Bucket Challenge have been adding significant value to spread awareness as well as raising funds for treatment developments. The ALS Ice Bucket Challenge went viral and raises approximately USD 2.2 million, which have been submitted for funding the development and trial for new ALS drug.
Europe, with comparatively higher ALS incidence (2.6 per 100,000), is expected to lead the global market, given the premium healthcare benefits provided by the government. The Asia Pacific amyotrophic lateral sclerosis market is projected to witness exponential growth. The rising geriatric population is fuelling several technical advancements in the healthcare sector to facilitate the best resources to the patients. Moreover, the region has also been experiencing a massive influx of foreign investments, which can be attributed to the easy availability and affordability of resources.
Amyotrophic Lateral Sclerosis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Orion Corporation
- Bausch Health Companies Inc.
- CYTOKINETICS, INC.
- Aquestive Therapeutics, Inc.
- Sanofi
- Covis Pharma
- Sun Pharmaceuticals Industries Ltd
- Mitsubishi Tanabe Pharma Corporation
- BrainStorm Cell Limited
- ViroMed Co., Ltd
- Ionis Pharmaceuticals
- Genervon Biopharmaceuticals, LLC
- Biogen
- Orphazyme A/S
- F. Hoffmann-La Roche Ltd
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment Type |
|
| Breakup by Diagnosis Method |
|
| Breakup by End User |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Amyotrophic Lateral Sclerosis Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Amyotrophic Lateral Sclerosis Disease Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Amyotrophic Lateral Sclerosis Disease Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Amyotrophic Lateral Sclerosis Disease Epidemiology Forecast (2017-2032)
5.3.1 Germany Amyotrophic Lateral Sclerosis Disease Epidemiology Forecast (2017-2032)
5.3.2 France Amyotrophic Lateral Sclerosis Disease Epidemiology Forecast (2017-2032)
5.3.3 Italy Amyotrophic Lateral Sclerosis Disease Epidemiology Forecast (2017-2032)
5.3.4 Spain Amyotrophic Lateral Sclerosis Disease Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Amyotrophic Lateral Sclerosis Disease Epidemiology Forecast (2017-2032)
5.4 Japan Amyotrophic Lateral Sclerosis Disease Epidemiology Forecast (2017-2032)
6 Amyotrophic Lateral Sclerosis Market Overview – 7MM
6.1 Amyotrophic Lateral Sclerosis Market Historical Value (2017-2023)
6.2 Amyotrophic Lateral Sclerosis Market Forecast Value (2024-2032)
7 Amyotrophic Lateral Sclerosis Market Landscape – 7MM
7.1 Amyotrophic Lateral Sclerosis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Amyotrophic Lateral Sclerosis Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Diagnosis Method
8 Amyotrophic Lateral Sclerosis Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Amyotrophic Lateral Sclerosis Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Amyotrophic Lateral Sclerosis Market Segmentation – 7MM
11.1 Amyotrophic Lateral Sclerosis Market by Type
11.1.1 Market Overview
11.1.2 Sporadic ALS
11.1.3 Familial ALS
11.2 Amyotrophic Lateral Sclerosis Market by Treatment Type
11.2.1 Market Overview
11.2.2 Chemotherapy
11.2.3 Stem Cell Therapy
11.2.4 Physical Therapy
11.2.5 Others
11.3 Amyotrophic Lateral Sclerosis Market by Diagnosis Method
11.3.1 Market Overview
11.3.2 Electromyogram
11.3.3 MRI
11.3.4 Blood and Urine Tests
11.3.5 Spinal Tap
11.3.6 Muscle Biopsy
11.3.7 Others
11.4 Amyotrophic Lateral Sclerosis Market by End User
11.4.1 Market Overview
11.4.2 Hospitals and Clinics
11.4.3 Cancer Research Centres
11.4.4 Others
11.5 Amyotrophic Lateral Sclerosis Market by Distribution Channels
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Retail Pharmacy
11.5.4 Online Pharmacy
11.5.5 Others
11.6 Amyotrophic Lateral Sclerosis Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Amyotrophic Lateral Sclerosis Market
12.1 Amyotrophic Lateral Sclerosis Market Historical Value (2017-2023)
12.2 Amyotrophic Lateral Sclerosis Market Forecast Value (2024-2032)
12.3 Amyotrophic Lateral Sclerosis Market by Type
12.4 Amyotrophic Lateral Sclerosis Market by Treatment Type
13 EU-4 and United Kingdom Amyotrophic Lateral Sclerosis Market
13.1 Amyotrophic Lateral Sclerosis Market Historical Value (2017-2023)
13.2 Amyotrophic Lateral Sclerosis Market Forecast Value (2024-2032)
13.3 Germany Amyotrophic Lateral Sclerosis Market Overview
13.3.1 Amyotrophic Lateral Sclerosis Market by Type
13.3.2 Amyotrophic Lateral Sclerosis Market by Treatment Type
13.4 France Amyotrophic Lateral Sclerosis Market Overview
13.4.1 Amyotrophic Lateral Sclerosis Market by Type
13.4.2 Amyotrophic Lateral Sclerosis Market by Treatment Type
13.5 Italy Amyotrophic Lateral Sclerosis Market Overview
13.5.1 Amyotrophic Lateral Sclerosis Market by Type
13.5.2 Amyotrophic Lateral Sclerosis Market by Treatment Type
13.6 Spain Amyotrophic Lateral Sclerosis Market Overview
13.6.1 Amyotrophic Lateral Sclerosis Market by Type
13.6.2 Amyotrophic Lateral Sclerosis Market by Treatment Type
13.7 United Kingdom Amyotrophic Lateral Sclerosis Market Overview
13.7.1 Amyotrophic Lateral Sclerosis Market by Type
13.7.2 Amyotrophic Lateral Sclerosis Market by Treatment Type
14 Japan Amyotrophic Lateral Sclerosis Market
14.1 Amyotrophic Lateral Sclerosis Market Historical Value (2017-2023)
14.2 Amyotrophic Lateral Sclerosis Market Forecast Value (2024-2032)
14.3 Amyotrophic Lateral Sclerosis Market by Type
14.4 Amyotrophic Lateral Sclerosis Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Orion Corporation
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Bausch Health Companies Inc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 CYTOKINETICS, INC.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Aquestive Therapeutics, Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Sanofi
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Covis Pharma
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Sun Pharmaceuticals Industries Ltd
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Mitsubishi Tanabe Pharma Corporation
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 BrainStorm Cell Limited
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 ViroMed Co., Ltd
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Ionis Pharmaceuticals
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Genervon Biopharmaceuticals, LLC
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Biogen
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifictions
21.14 Orphazyme A/S
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 F. Hoffmann-La Roche Ltd
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Amyotrophic Lateral Sclerosis Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 716.3 million in 2023, driven by the increasing prevalence of ALS across the globe.
The market is anticipated to grow at a CAGR of 5.5% during the forecast period of 2024-2032, likely to reach a market value of USD 1159.1 million by 2032.
The market demand has increased owing to the increased emphasis on providing quality treatment for ALS affected people, which is driven by rising technical advancements in biotechnology and better understanding of human physiology.
The FDA has approved QALSODY™ (tofersen), the first drug that targets the genetic cause of ALS. Researchers have been focusing on stem therapies, gene therapies and combination therapies for offering effective and customised treatment.
The major regions of the market include the United States, Japan, EU-4, and the United Kingdom.
Major distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
Major end users include cancer research centres, hospitals and clinics, among others.
The market segmentation can be divided into sporadic and familial ALS.
Common treatment methods include chemotherapy, stem cell therapy, and physical therapy, among others.
Electromyogram, MRI, blood and urine tests, spinal tap, and muscle biopsy, among others, are some major diagnostic methods used in the market.
Key players involved in the market are Orion Corporation, Bausch Health Companies Inc., CYTOKINETICS, INC., Aquestive Therapeutics, Inc., Sanofi, Covis Pharma, Sun Pharmaceuticals Industries Ltd., Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Limited, ViroMed Co., Ltd, Ionis Pharmaceuticals, Genervon Biopharmaceuticals, LLC, Orphazyme A/S, F. Hoffmann-La Roche Ltd., and Biogen.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER